RE:RE:RE:Q3 Report...Very Good but US not soThat's a great summary of the entire business.
The additional product launches next year will continue to increase product revenue growth.
26% market share for Epuris is encouraging and as a user of the product myself, it really is a great product.
Not sure when Latin America will come around but when it does, royalty income will increase.
Future pipeline like CF101 is gaining more momentum to pass phase III trial.
The CEO had to be let go as the U.S. acquisition was terrible. $40+ million for a $10 million a year company whose main driver was a cold sore relief drug was laughable.